IFM Investors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.29M | Buy |
93,394
+8,771
| +10% | +$584K | 0.04% | 359 |
|
|
2026
Q1 | $5.31M | Buy |
84,623
+2,406
| +3% | +$168K | 0.04% | 356 |
|
|
2025
Q4 | $5.46M | Hold |
82,217
| – | – | 0.05% | 340 |
|
|
2025
Q3 | $5.52M | Buy |
82,217
+405
| +0.5% | +$32K | 0.05% | 323 |
|
|
2025
Q2 | $7.14M | Buy |
81,812
+7,619
| +10% | +$597K | 0.07% | 267 |
|
|
2025
Q1 | $5.07M | Hold |
74,193
| – | – | 0.05% | 317 |
|
|
2024
Q4 | $5.77M | Sell |
74,193
-6,601
| -8% | -$489K | 0.06% | 309 |
|
|
2024
Q3 | $5.42M | Buy |
80,794
+415
| +0.5% | +$34.1K | 0.05% | 340 |
|
|
2024
Q2 | $9.11M | Buy |
80,379
+696
| +0.9% | +$88K | 0.09% | 206 |
|
|
2024
Q1 | $11.1M | Sell |
79,683
-901
| -1% | -$113K | 0.12% | 168 |
|
|
2023
Q4 | $10M | Sell |
80,584
-774
| -1% | -$79.1K | 0.12% | 171 |
|
|
2023
Q3 | $7.59M | Buy |
81,358
+2,943
| +4% | +$332K | 0.1% | 208 |
|
|
2023
Q2 | $10.1M | Buy |
78,415
+5,115
| +7% | +$619K | 0.13% | 149 |
|
|
2023
Q1 | $8.52M | Buy |
73,300
+1,086
| +2% | +$122K | 0.13% | 163 |
|
|
2022
Q4 | $8.18M | Buy |
72,214
+4,588
| +7% | +$504K | 0.14% | 159 |
|
|
2022
Q3 | $5.45M | Buy |
67,626
+2,142
| +3% | +$181K | 0.1% | 223 |
|
|
2022
Q2 | $4.88M | Buy |
65,484
+2,056
| +3% | +$188K | 0.09% | 246 |
|
|
2022
Q1 | $8.11M | Buy |
63,428
+13,024
| +26% | +$1.42M | 0.13% | 165 |
|
|
2021
Q4 | $6.77M | Sell |
50,404
-384
| -0.8% | -$55.2K | 0.12% | 151 |
|
|
2021
Q3 | $6.94M | Buy |
50,788
+372
| +0.7% | +$46.9K | 0.14% | 133 |
|
|
2021
Q2 | $5.38M | Buy |
50,416
+8,280
| +20% | +$795K | 0.11% | 185 |
|
|
2021
Q1 | $3.79M | Buy |
42,136
+6,032
| +17% | +$566K | 0.1% | 209 |
|
|
2020
Q4 | $3.34M | Buy |
36,104
+5,760
| +19% | +$514K | 0.11% | 189 |
|
|
2020
Q3 | $3.13M | Buy |
30,344
+3,324
| +12% | +$347K | 0.13% | 146 |
|
|
2020
Q2 | $2.74M | Sell |
27,020
-10,536
| -28% | -$942K | 0.14% | 144 |
|
|
2020
Q1 | $2.61M | Sell |
37,556
-1,464
| -4% | -$91.1K | 0.12% | 169 |
|
|
2019
Q4 | $2.13M | Buy |
39,020
+2,080
| +6% | +$98.7K | 0.08% | 275 |
|
|
2019
Q3 | $1.38M | Buy |
36,940
+11,716
| +46% | +$455K | 0.05% | 374 |
|
|
2019
Q2 | $945K | Buy |
25,224
+4,840
| +24% | +$152K | 0.05% | 369 |
|
|
2019
Q1 | $607K | Hold |
20,384
| – | – | 0.04% | 446 |
|
|
2018
Q4 | $611K | Buy |
+20,384
| New | +$647K | 0.05% | 399 |
|
Other funds holding DXCM
IFM Investors's DXCM Position: Q2 2026 in Review
IFM Investors increased its DexCom (DXCM) stake by 10% in Q2 2026, buying an estimated $584K and bringing the position to 93,394 shares worth $6.29M. The position accounts for 0.04% of the portfolio, ranked #359.
IFM Investors first reported a position in DXCM in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.1M in Q1 2024. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- IFM Investors held 93,394 shares of DexCom worth $6.29M as of Q2 2026.
- IFM Investors bought 8,771 DexCom shares in Q2 2026, an estimated $584K.
- DexCom made up 0.04% of IFM Investors's portfolio in Q2 2026, its #359 holding.
- IFM Investors first reported a position in DexCom in Q4 2018 and has held it in 31 quarters since.
- IFM Investors's DexCom position peaked at $11.1M in Q1 2024.
- 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.